Can Veterans Claim High Cholesterol as a VA Disability? Rating Rules and Secondary Pathways

Yes, but almost never for the cholesterol itself. The VA rating schedule contains no diagnostic code for hyperlipidemia, so a stand-alone claim is usually granted at 0 percent, which establishes service connection but pays nothing. Payment becomes realistic only when high cholesterol is tied to something else: a service-connected condition that caused it, a drug VA prescribed for a service-connected condition, or the arterial damage it helped create. What follows explains how the rating schedule measures disability, which secondary routes succeed, and why filing high cholesterol as a VA disability on its own rarely produces a check.

Why the Rating Schedule Has No Cholesterol Line

The Veterans Affairs Schedule for Rating Disabilities is a deficit system. Every diagnostic code in 38 CFR Part 4 asks the same question: how much function has this person lost? A knee is rated by range of motion. A heart is rated by metabolic equivalents. A lung is rated by forced expiratory volume. Cholesterol is a laboratory number with no functional signature, so the schedule has nothing to measure.

Part 4 runs roughly 15 body-system chapters and more than 1,000 diagnostic codes. None of them is titled hyperlipidemia or hypercholesterolemia. When an unlisted condition appears, adjudicators turn to 38 CFR §4.100, which permits rating by analogy to the closest listed code. For lipid disorders, that analogy most often lands on Diagnostic Code 7999, the endocrine catch-all for "any other disabling condition." Adjudicators vary, but the outcome is consistent: an asymptomatic lipid abnormality maps to a 0 percent evaluation.

That 0 percent is not a denial, and the distinction matters. A grant at 0 percent establishes service connection, opens the door to secondary claims built on that connection, and authorizes VA treatment of the condition. What it does not do is generate compensation. In plain terms: the VA will agree you have high cholesterol, then pay you nothing for it, because the schedule pays for lost function rather than for abnormal lab values.

The functional consequences do pay. Coronary artery disease sits at Diagnostic Code 7005 and is rated on exercise capacity measured in metabolic equivalents, or METs. A veteran limited to 3 METs or less scores 100 percent. Capacity of 3.1 to 5.0 METs scores 60 percent, 5.1 to 7.0 scores 30 percent, and 7.1 to 10.0 scores 10 percent. Hypertension carries its own code at 7101. Those numbers exist because ischemia produces measurable limits; a lipid panel does not.

What the Rating Rules Actually Measure

Three thresholds decide most lipid-related claims, and they answer different questions. An LDL of 190 mg/dL or higher flags possible familial hypercholesterolemia and justifies statin therapy regardless of other risk factors, per the 2018 AHA/ACC multisociety cholesterol guideline. A ten-year atherosclerotic risk of 7.5 percent or higher triggers a moderate-intensity statin discussion, and 20 percent or higher pushes toward high-intensity treatment. Separately, a 70 percent cross-sectional stenosis is roughly where a coronary plaque begins to limit flow and produce exertional symptoms. These are severity, treatment-decision, and flow-limitation thresholds respectively, not rival definitions of "high."

Statin intensity is defined by expected effect rather than by dose alone. High-intensity therapy, meaning atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg, lowers LDL by 50 percent or more. Moderate intensity lowers it 30 to 49 percent. The Cholesterol Treatment Trialists' Collaboration reported in 2010 that every 39 mg/dL reduction in LDL produced about a 22 percent relative drop in major vascular events. That figure is the engine behind the whole treatment paradigm.

None of those numbers appear in a rating decision. Compensation tracks organ damage, so a veteran with an LDL of 220 mg/dL and a normal stress test receives 0 percent, while a veteran with an LDL of 130 mg/dL and angina at 4 METs receives 60 percent. The payment gap is not marginal. A 10 percent evaluation paid about USD 176 a month in the 2026 rate table, and a 100 percent evaluation paid about USD 3,843 a month. The difference between the two veterans above is roughly USD 1,400 a month at 60 percent.

There is a second trap. Under 38 CFR §4.14, the VA will not pyramid evaluations, meaning it will not compensate the same disability twice under two codes. A veteran already rated for diabetic cardiovascular complications generally cannot stack a separate hyperlipidemia rating on the same underlying process. The lipid disorder has to show effects that are genuinely distinct from what the primary rating already captures.

Secondary Pathways for High Cholesterol as a VA Disability

Secondary service connection under 38 CFR §3.310(a) is where most successful claims live. The rule states that a disability is service connected if it is proximately due to or the result of a service-connected disease or injury. The causal chain, not the cholesterol, is the claim.

Psychiatric medications are the most underused pathway. Atypical antipsychotics and several antidepressants produce weight gain, insulin resistance, and dyslipidemia as documented metabolic effects. A veteran service connected for PTSD at 70 percent whose VA-prescribed quetiapine coincided with a 20-pound weight gain and a jump in triglycerides has a coherent secondary claim. The evidence that wins is the prescription record, the dated weight trajectory, and the lipid trend, laid side by side.

Endocrine conditions form a second chain. Hypothyroidism at Diagnostic Code 7903 slows lipid clearance and commonly elevates LDL and total cholesterol. Service-connected hypothyroidism that produces a lipid disorder supports secondary service connection even though the lipid disorder itself rates at 0 percent. The value is in the linkage, which can support a higher combined evaluation and future claims.

Statin complications are the third and most neglected chain. Statins prescribed for a service-connected condition can cause muscle injury, and that injury is ratable in its own right. Rhabdomyolysis with residual renal impairment can be rated under renal codes at 10 to 60 percent, and statin myopathy with persistent weakness can be rated by analogy under musculoskeletal codes. Statin therapy also modestly raises incident diabetes risk, roughly 10 to 12 percent in randomized trials, which opens another secondary chain when the veteran was already service connected.

The Timeline Behind the Lab Value

Atherosclerosis begins decades before it appears on any claim form, which is why a veteran's cholesterol reading at discharge predicts so little. The process starts in adolescence with fatty streaks, thin collections of lipid-laden foam cells inside the arterial intima. Plasma LDL near 100 mg/dL is already enough to drive accumulation; no threshold has to be crossed for the disease to start.

The counterintuitive row is the last one. The PROSPECT trial, published in 2011, followed patients after acute coronary events and found that the lesions that actually caused the events were usually not the tightest ones on prior imaging. Most acute infarctions arise from plaques causing less than 70 percent stenosis, because what ruptures is a thin-capped inflammatory plaque rather than a calcified narrow one. In plain terms: a clean angiogram showing "only" 50 percent blockages does not mean the risk has passed, and a veteran whose first cardiac symptom is a heart attack is following the common path, not an unusual one.

This biology explains why the rating schedule waits for organ damage. The 30-plus year lag between the first fatty streak and the first infarction means that a veteran discharged at 25 with an LDL of 160 mg/dL has a plausible future claim, but no present functional loss. The claim that works today is the medication side effect, the endocrine chain, or the presumptive condition.

Misconceptions That Sink Claims

The most common error is filing for the diagnosis rather than the consequence. A veteran who submits a lipid panel and a nexus letter saying "high cholesterol is related to service" will usually receive a 0 percent grant, then conclude the system failed. The system did what the schedule requires. The productive version of the same claim names the functional loss or names the service-connected condition that caused the lipid disorder.

The second error is treating a 0 percent decision as a loss. A 0 percent grant preserves the effective date, keeps the condition service connected for life, and authorizes treatment. Because ratings can be increased later, a 0 percent evaluation filed at discharge can protect an effective date that becomes financially meaningful fifteen years later when angina appears.

Agent Orange is the third trap. Ischemic heart disease is presumptive for qualifying Vietnam veterans under 38 CFR §3.309(e). Hyperlipidemia is not on that list and never has been. Veterans who served in the relevant window should claim the heart disease directly and let the lipid disorder ride along as secondary if it is separately manifested, rather than claiming the lipid disorder and hoping the presumption stretches.

The fourth misconception concerns statin side effects. Muscle complaints are reported by 5 to 20 percent of patients in observational settings but by roughly 1 percent in blinded randomized trials, a gap that reflects expectation effects as much as pharmacology. A claim built only on a veteran's account of muscle aches will struggle. A claim built on documented creatine kinase elevation, a positive dechallenge, and a recurrence on rechallenge is a different document entirely.

A fifth error involves assuming lab values prove disability. They do not, and no amount of serial lipid panels substitutes for a stress test, an ejection fraction, or a measured work capacity. The rating follows the examination, not the spreadsheet.

Red Flags, and What to Actually Do

Some findings change the priority order of a claim. These are the ones that warrant immediate clinical attention rather than claim strategy:

• Muscle pain with dark, cola-colored urine or dramatically reduced urine output, suggesting rhabdomyolysis
• Creatine kinase above roughly ten times the upper limit of normal in a veteran on a statin
• New exertional chest pressure, jaw pain, or breathlessness at low exertion, particularly if it resolves with rest
• LDL above 190 mg/dL with a family history of early heart attack, pointing toward familial hypercholesterolemia
• Tendon xanthomas or corneal arcus before age 45, which are physical signs of longstanding severe hypercholesterolemia
• Unexplained weight gain of 7 percent or more within months of starting an atypical antipsychotic

For the claim itself, sequence matters more than volume. File an Intent to File first, which preserves an effective date for up to twelve months while evidence is gathered. Request the service treatment records and, separately, the VA prescription history, because the medication start dates are the spine of any secondary claim. Ask the treating clinician for a written opinion that addresses causation in the language of 38 CFR §3.310, not simply a note that the veteran has high cholesterol.

If a mental health medication is the suspected cause, obtain the weight and lipid values from before and after the prescription start date. A two-point trend with dates is far stronger than a narrative. If hypothyroidism or diabetes is the anchor, confirm the primary condition is already service connected before building the secondary layer.

Finally, do not abandon a 0 percent grant. Request a higher evaluation only when a genuine functional change exists, and otherwise leave the grant in place to protect the effective date. Reopening without new evidence risks nothing financially but wastes a year.

Limits of the Evidence

Several parts of this picture remain genuinely uncertain. The causal contribution of a single medication to a specific veteran's lipid disorder cannot be proven with certainty, because metabolic changes unfold against a background of aging, diet, and genetics. Clinicians and adjudicators work in probabilities, and a nexus opinion is an argument rather than a measurement.

The analogy to Diagnostic Code 7999 is a convention, not a codified rule. Adjudicators have applied other codes to lipid disorders depending on which manifestations dominate, and outcomes across regional offices are not perfectly uniform despite the consistency requirements in 38 CFR §4.7. Veterans with unusual presentations should expect variation.

The statin-diabetes signal is real but modest, and it is smaller than the cardiovascular benefit the same drugs deliver. Veterans weighing a secondary claim over a medication decision should separate the two questions entirely. The claim follows the medical record; the medical record should follow the cardiology evidence, which still favors treatment for most high-risk patients.

Finally, the atherosclerosis timeline describes population averages. Individual plaques progress at very different rates, and some veterans reach 70 percent stenosis by 50 while others never do. The numbers in the table above are a planning tool, not a prognosis, and no rating decision should be built on an assumption about where any individual sits on that curve.